MARKET

APTO

APTO

Aptose Bioscienc
NASDAQ
1.660
+0.160
+10.67%
After Hours: 1.670 +0.01 +0.60% 18:37 03/28 EDT
OPEN
1.500
PREV CLOSE
1.500
HIGH
1.700
LOW
1.500
VOLUME
137.09K
TURNOVER
0
52 WEEK HIGH
10.13
52 WEEK LOW
1.360
MARKET CAP
26.09M
P/E (TTM)
-0.2109
1D
5D
1M
3M
1Y
5Y
Aptose Biosciences’ Strategic Shift to Front-Line AML Therapy Garners Buy Rating
TipRanks · 1d ago
Aptose Biosciences Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 1d ago
Aptose Biosciences Price Target Maintained With a $23.00/Share by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Maintains Buy on Aptose Biosciences, Maintains $23 Price Target
Benzinga · 1d ago
APTO Stock Earnings: Aptose Biosciences Beats EPS for Q4 2023
Aptose Biosciences reported results for the fourth quarter of 2023. The company did not report any revenue for the quarter. Aptose reported earnings per share of -$1.44. This was above the analyst estimate for EPS of - $1.59.
Investorplace · 2d ago
Aptose Biosciences Expands AML Treatment Trials
TipRanks · 2d ago
Aptose Biosciences Q4 EPS $(1.44) Beats $(1.59) Estimate
Benzinga · 2d ago
Recap: Aptose Biosciences Q4 Earnings
Aptose Biosciences reported its Q4 earnings on March 26. The company beat estimates by 9.0%. The company's revenue was down $0 from the same period last year. Last quarter the company's earnings were followed by a 24.0% drop in the share price.
Benzinga · 2d ago
More
About APTO
Aptose Biosciences Inc. is a clinical-stage biotechnology company. The Company is engaged in the development and commercialization of precision medicines addressing unmet clinical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspetinib (HM43239), an oral, myeloid kinase inhibitor being studied as monotherapy and in combination therapy in the APTIVATE international Phase I/II expansion trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib (CG-806), an oral, dual lymphoid and myeloid kinase inhibitor in Phase I a/b stage development for the treatment of patients with relapsed or refractory hematologic malignancies.

Webull offers Aptose Biosciences Inc stock information, including NASDAQ: APTO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APTO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APTO stock methods without spending real money on the virtual paper trading platform.